Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
Laurent Castera,Philippe Garteiser,Cédric Laouenan,Tiphaine Vidal-Trécan,Anaïs Vallet-Pichard,Pauline Manchon,Valérie Paradis,Sébastien Czernichow,Dominique Roulot,Etienne Larger,Stanislas Pol,Pierre Bedossa,Jean-Michel Correas,Dominique Valla,Jean-François Gautier,Bernard E Van Beers,QUID NASH investigators,Djamila Bellili,Ouarda Bessadi,Charlene Da Silveira,Fatima Zohra Djelouat,Benoit Girard,Vanessa Legrand,Nathalie Neveux,Meriam Meziani,Ludovic Roy,Dahia Sekour,Manon Sens,Miassa Slimani,Ouassila Zatout,Delphine Bachelet,Krishna Bhavsar,Basma Basli-Baillet Jimmy Mullaert,Estelle Marcault,Nassima Si-Mohammed,Emmanuel Cosson,Miguel Albuquerque,Sabrina Doblas,Adel Hammoutene,Estefania Gonzalez Montpetit,Gwenaël Pagé,Béatrice Parfait,Catherine Postic,Agnès Lehuen,Amine Toubal,Camille Rousseau,Blandine Fruchet,Pauline Soulard,Zouriatou Gouda,Michel Vidaud,Franck Letourneur,Gilles Renault,Raphaël Scharfmann,Amel Ait-Boudaoud,Charles Barsamian,Claire Carette,Claire Rives-Lange,Rachel Baida,Olivier Couture,Sofiane Decombas,Thomas Deffieux,Thu-Mai Nguyen,Mickael Tanter,Tania Baltauss,Edwige-Ludiwyne Balzac,Pierre Barbier Saint Hilaire,Philippe Delerive,Valérie Duvivier,Arnaud Fillon,Julia Geronimi,Jessica Laplume,Erwan Werner,Laura Xuereb,Robin Liechti,Olivier Martin,Florence Mehl,Manuela Pruess,Jean-Marie Castille,Fabienne Drane,Olivier Deckmyn,Florence Castelli,Benoit Colsch Emmanuel Cousin,François Fenaille,Laure Guilbaud,Allyre Lohier,Francois Chambellin,Lyddie Laaland,Catherine Clusel,Marie Hauduroy,Pierre Pautre
DOI: https://doi.org/10.1016/j.jhep.2024.03.023
Abstract:Background & aims: Non-invasive scores have been proposed to identify patients with fibrotic, metabolic dysfunction-associated steatohepatitis (MASH), who are at the highest risk of progression to complications of cirrhosis and may benefit from pharmacologic treatments. However, data in patients with type 2 diabetes (T2DM) are lacking. The aim of this multicenter prospective study was to perform a head-to-head comparison of FAST (FibroScan-aspartate aminotransferase [AST]), MAST (MRI-AST), MEFIB (magnetic resonance elastography [MRE] plus FIB-4), and FNI (fibrotic NASH index) for detecting fibrotic MASH in patients with T2DM. Methods: A total of 330 outpatients with T2DM and biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) from the QUID-NASH study (NCT03634098), who underwent FibroScan, MRI-proton density fat fraction and MRE at the time of liver biopsy were studied. The main outcome was fibrotic MASH, defined as NAS ≥4 (with at least one point for each parameter) and fibrosis stage ≥2 (centrally reviewed). Results: All data for score comparisons were available for 245 patients (median age 59 years, 65% male, median BMI 31 kg/m2; fibrotic MASH in 39%). FAST and MAST had similar accuracy (AUROCs 0.81 vs. 0.79, p = 0.41) but outperformed FNI (0.74; p = 0.01) and MEFIB (0.68; p <0.0001). When using original cut-offs, MAST outperformed FAST, MEFIB and FNI when comparing the percentage of correctly classified patients, in whom liver biopsy would be avoided (69% vs. 48%, 46%, 39%, respectively; p <0.001). When using cut-offs specific to our population, FAST outperformed FNI and MAST (56% vs. 40%, and 38%, respectively; p <0.001). Conclusion: Our findings show that FAST, MAST, MEFIB and FNI are accurate non-invasive tools to identify patients with T2DM and fibrotic MASH in secondary/tertiary diabetes clinics. Cut-offs adapted to the T2DM population should be considered. Impact and implications: Among patients with type 2 diabetes (T2DM), identifying those with metabolic dysfunction-associated steatohepatitis and significant fibrosis, who are the most at risk of developing clinical liver-related outcomes and who may benefit from pharmacologic treatments, is an unmet need. In this prospective multicenter study, we compared four non-invasive scores, three based on imaging (MRI or ultrasound technologies) and one on laboratory blood tests, for this purpose, using original and study-specific cut-offs. Our findings show that FAST, MAST, MEFIB and FNI are accurate non-invasive tools to identify patients with T2DM and fibrotic MASH in secondary/tertiary diabetes clinics. Cut-offs adapted to the T2DM population should be considered. Trial registration number: NCT03634098.